ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · IEX Real-Time Price · USD
17.77
+0.12 (0.68%)
Jul 12, 2024, 4:00 PM EDT - Market closed

Company Description

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States.

The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.

It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer’s disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms.

It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS.

The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997.

ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals logo
Country United States
Founded 1993
IPO Date May 27, 2004
Industry Biotechnology
Sector Healthcare
Employees 598
CEO Stephen R. Davis J.D.

Contact Details

Address:
12830 El Camino Real, Suite 400
San Diego, California 92130
United States
Phone 858-558-2871
Website acadia-pharm.com

Stock Details

Ticker Symbol ACAD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001070494
CUSIP Number 004225108
ISIN Number US0042251084
Employer ID 06-1376651
SIC Code 2834

Key Executives

Name Position
Stephen R. Davis J.D. President, Chief Executive Officer and Director
Mark C. Schneyer Executive Vice President and Chief Financial Officer
Brendan P. Teehan Executive Vice President, Chief Operating Officer and Head of Commercial
James K. Kihara Vice President, Chief Accounting Officer and Corporate Controller
Dr. Elizabeth H.Z. Thompson Ph.D. Executive Vice President and Head of Research and Development
Benir Ruano Senior Vice President of Technical Development and Operations
Albert S. Kildani Senior Vice President of Investor Relations and Corporate Communications
Jennifer J. Rhodes J.D. Executive Vice President, Chief Legal Officer and Secretary
Julie Fisher Senior Vice President of Marketing and Commercial Strategy
Holly Valdiviez Senior Vice President and Head of Sales

Latest SEC Filings

Date Type Title
May 29, 2024 8-K Current Report
May 29, 2024 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
May 29, 2024 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
May 29, 2024 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
May 29, 2024 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
May 29, 2024 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
May 29, 2024 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
May 29, 2024 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
May 29, 2024 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
May 29, 2024 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments